Skip to main content
SpringerLink
Log in

Recent Developments in Hormonal Contraception

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Asbell B. The Pill: A Biography of the Drug That Changed the World. New York: Random House, 1995.

    Google Scholar 

  2. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998;57:315-324.

  3. Effect of different progestagens in low oestrogen oral contraceptives on venos thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-1588.

  4. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-1582.

  5. Sullivan JM, Lobo RA. Considerations for contraception in women with cardiovascular disorders. Am J Obstet Gynecol 1993;168:2006-2011.

    Google Scholar 

  6. Harlap S, Kost K, Forrest JD. Preventing Pregnancy, Protecting Health: A New Look at Birth Control Choices in the United States. NewYork: The Alan Guttmacher Institute, 1991.

    Google Scholar 

  7. Rodrigues I, Grou F, Joly J. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse. Am J Obstet Gynecol 2001;184:531-537.

    Google Scholar 

  8. ACOG Practice Bulletin 25, 2001.

  9. WHO Family Planning and Population. Emergency Contraception: A Guide for Service Delivery, Geneva, 1998.

  10. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352:428-433.

  11. Grimes D, Raymond E, Scott Jones B. Emergency contraception over-the-counter: the medical and legal imperatives. Obstet Gynecol 2001;98:151-155.

    Google Scholar 

  12. Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994;94:687-694.

    Google Scholar 

  13. Speroff L, Darney P. A Clinical Guide for Contraception. Philadelphia: Lippincott Williams & Wilkins, 2001.

    Google Scholar 

  14. Westhoff C, Truman C, Kalmuss D, Cushman L, Davidson A, Rulin M, Heartwell S. Depressive symptoms and Depo-Provera. Contraception 1998;57:237-240.

    Google Scholar 

  15. Sangi-Haghpeykar P, Poindexter A, Bateman L, Ditmore J. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 1996;88:227-233.

    Google Scholar 

  16. Jimenez J, Ochoa M, Soler MP, Portales P. Long-term follow-up of children breast-fed by mothers receiving depot-medroxyprogesterone acetate. Contraception 1984;30:523-533.

    Google Scholar 

  17. Sang GW, Shao QX, Ge RS, Chen J, Chen X, Li M, Wu S, Sun G, Zhou H, Zhang S, Zhu L, Ye B, Zhang J, Ma F, Jiang B, Zhou Z, Dong Q, Shenn H, Liu Y, Shao J, Wang S, Ming H, Zhy Z, Cheng H, Chen S, Yu H, Zhang Z, Qing Y, Wang X, Hall P, d'Arcangues C, Snow R. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception 1995;51:185-192

    Google Scholar 

  18. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bull World Health Organ 1993;71:677-689.

  19. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1988;37:1-20.

  20. Kaunitz AM, Garceau RJ, Cromie MA, the Lunelle Study Group. Comparative safety, efficacy, and cycle control of Lunelle\(^{\bigcirc TM}\) monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 1999;60:179.

    Google Scholar 

  21. Hall P, Bahamondes L, Diaz J, Petta C. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Columbia, and Peru. Contraception 1997;56:353-359.

    Google Scholar 

  22. Garza-Flores J, Morales del Olmo A, Fuziwara J, Figueroa J, Alonso A, Monroy J, Perez M, Urbina-Fuentes M, Guevara S, Cedeno E, Barrios R, Ferman J, Medina L, Velezques E, Perez-Palacios G. Introduction of Cyclofem once-a-month injectable contraceptive in Mexico. Contraception 1998;58:7-12.

    Google Scholar 

  23. Cuong D, Hung M. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem in Vietnamese women. Contraception 1996;54:169-179.

    Google Scholar 

  24. A multicentered phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1989;40:531-551.

  25. Jain JK, Ota F, Mishell DR. Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive. Contraception 2000;61:195-198.

    Google Scholar 

  26. Bahamondes L, Lavin P, Ojeda G, Petra C, Diaz J, Maradiegue E, Monteiro I. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem. Contraception 1997;55:307-310.

    Google Scholar 

  27. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-77.

    Google Scholar 

  28. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.

    Google Scholar 

  29. Sivin I, Stern J, Diaz S, Pavez M, Alvarez F, Brache V, Mishell D, Lacarra M, McCarathey T, Holma P, Darney P, Klaisle C, Olsson S-E, Odlind V. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol 1992;166:1208-1213.

    Google Scholar 

  30. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.

    Google Scholar 

  31. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-362.

    Google Scholar 

  32. Sivin I, Stern J, Coutinho E, Mattos C, El Mahgoub S, Diaz S, Pavez M, Alvarez F, Brache V, Thevinin F, Dias J, Faudes A, Dias MM, McCarathey T, Mishell D, Shoupe D. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 AgIUDs. Contraception 1991;44:473-480.

    Google Scholar 

  33. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702.

    Google Scholar 

  34. Crosignani P, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-263.

    Google Scholar 

  35. Anderson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynecol 1990;97:690-694.

    Google Scholar 

  36. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-77.

    Google Scholar 

  37. Hubacher D, Lara-Ricalde R, Taylor D, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-567.

    Google Scholar 

  38. Farley M, Rosenberg M, Rowe PJ, Chen J-H, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-788.

    Google Scholar 

  39. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel-and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-264.

    Google Scholar 

  40. Pakarinen PI, Suvisaari J, Luukkainen T, Lahteenmaki P. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril 1997;68:59-64.

    Google Scholar 

  41. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865-870.

    Google Scholar 

  42. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16:469-475.

    Google Scholar 

  43. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy G, Fisher A. For the Ortho Evra/Evra 001 Study Group. Transdermal contraception: evaluation of three trandermal norelgestromin/ethinyl estradiol doses in a randomized multicenter, dose-response study. Am J Obstet Gynecol 2001;186:15-20.

    Google Scholar 

  44. Audet MC, Moreau M, Koltun WD, Waldbaum A, Shangold G, Fisher A, Creasy G. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled tnal. JAMA 2001;285:2347-2354.

    Google Scholar 

  45. Zhng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1-8.

    Google Scholar 

  46. Herjan JT, Bennink HC. Introduction: presentation of clinical data on Implanon. Contraception 1998;58:85S.

    Google Scholar 

  47. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(Suppl. 2):21-28.

    Google Scholar 

  48. Meirik O, Farley T, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device and sterilization. Obstet Gynecol 2001;97:539-547.

    Google Scholar 

  49. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998;58:109S-115S.

    Google Scholar 

  50. Stewart F, Harper C, Ellertson C, Grimes D, Sawaya G, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA 2001;285:2232-2239.

    Google Scholar 

  51. Sawaya G, Harper C, Balistreri E, Boggess J, Darney P. Cervical neoplasia risk in women provided hormonal contraception without a Pap smear. Contraception 2001;63:57-60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco General Hospital, University of California, San Francisco, CA, 94110, USA

    Eleanor A. Drey & Philip D. Darney

Authors
  1. Eleanor A. Drey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip D. Darney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip D. Darney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drey, E.A., Darney, P.D. Recent Developments in Hormonal Contraception. Rev Endocr Metab Disord 3, 257–265 (2002). https://doi.org/10.1023/A:1020080627635

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020080627635

Search

Navigation